Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy

Claudia Brandt, Patricia Seja, Kathrin Töllner, Kerstin Römermann, Philip Hampel, Markus Kalesse, Andi Kipper, Peter W. Feit, Kasper Lykke, Trine Lisberg Toft-Bertelsen, Pauliina Paavilainen, Inkeri Spoljaric, Martin Puskarjov, Nanna MacAulay, Kai Kaila, Wolfgang Löscher

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalNeuropharmacology
Volume143
Pages (from-to)186-204
Number of pages19
ISSN0028-3908
DOIs
Publication statusPublished - Dec 2018
MoE publication typeA1 Journal article-refereed

Bibliographical note

Correction
Volume: 143
Pages: 349-350
DOI: 10.1016/j.neuropharm.2018.10.012

Fields of Science

  • Epilepsy
  • Anti-seizure drugs
  • Neonatal seizures
  • GABA
  • Giant depolarizing potentials
  • CATION-CHLORIDE COTRANSPORTERS
  • GIANT DEPOLARIZING POTENTIALS
  • WATER PERMEABILITY
  • PILOCARPINE MODEL
  • ANIMAL-MODELS
  • PYRAMIDAL NEURONS
  • DRUG DISCOVERY
  • KINDLED RATS
  • GABA ACTIONS
  • AQUAPORIN 4
  • 3112 Neurosciences
  • 1184 Genetics, developmental biology, physiology

Cite this

Brandt, C., Seja, P., Töllner, K., Römermann, K., Hampel, P., Kalesse, M., Kipper, A., Feit, P. W., Lykke, K., Toft-Bertelsen, T. L., Paavilainen, P., Spoljaric, I., Puskarjov, M., MacAulay, N., Kaila, K., & Löscher, W. (2018). Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy. Neuropharmacology, 143, 186-204. https://doi.org/10.1016/j.neuropharm.2018.09.025